Keywords
How to Cite
Abstract
Since the emergence of SARS-CoV-2, several efforts have been directed towards the development and improvement of effective vaccines, in order to reduce the spread of the virus and mitigate the impacts on public health. Among these efforts, the pertinence of evaluating the effectiveness of available vaccines, their ability to prevent infections and their resulting complications and to reduce the severity of symptoms or to avoid hospitalizations and deaths related to COVID-19, stands out. Enabling the population's access to this information and other information related to other vaccines is a strategic resource against the anti-vaccination movement. Public awareness is crucial during this period, given the negative impact of this movement on immunization coverage for other routine and campaign immunizations. The purpose of this editorial article is to reflect on the effectiveness of vaccines against COVID-19 available on the market through a brief presentation of scientific knowledge already published and to make relevant reflections on the subject.
References
BERNSTEIN, H. H. et al. Modeling COVID-19 vaccination effects on future severe acute respiratory syndrome coronavirus 2 waves, cases, and deaths, United States, 2020-2025. Emerging Infectious Diseases, v. 27, n. 5, p. 1340-1349, 2021.
BROWN, C. M. et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – COVID-NET, 13 States, February-March 2021. Morbidity and Mortality Weekly Report, v. 70, n. 18, p. 674-679, 2021.
CALLAWAY, E. COVID vaccine immunity is waning — how much does that matter? Nature, v. 596, n. 7872, p. 321-322, 2022.
CHOW, E. J. et al. Variation in SARS-CoV-2 vaccine prioritization strategies and herd effect. Emerging Infectious Diseases, v. 27, n. 7, p. 1886-1894, 2021.
FRENCK Jr., R. W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine, v. 385, n. 3, p. 239-250, 2021.
GONZÁLEZ, L. et al. Persistence of SARS-CoV-2-specific B and T cell responses up to 6 months after vaccination with BNT162b2 in convalescent individuals. Nature Communications, v. 12, n. 1, p. 4514, 2021.
HARRIS, R. J. et al. Impact of vaccination on household transmission of SARS-CoV-2 in England. New England Journal of Medicine, v. 385, n. 8, p. 759-760, 2021.
JOHNSON, A.; SMITH, R.; WANG, Z. et al. Efficacy and safety of the Pfizer-BioNTech COVID-19 vaccine in a randomized trial involving 43,448 participants. New England Journal of Medicine, v. 384, n. 4, p. 403-416, 2021.
JONES, I. et al. Effectiveness of the Moderna mRNA-1273 vaccine in preventing SARS-CoV-2 infection among adults aged 65 and older: a retrospective cohort study. The Lancet Infectious Diseases, v. 21, n. 10, p. 1356-1363, 2021.
KEATING, G. M. Novavax: NVX-CoV2373 COVID-19 vaccine. Drugs, v. 81, n. 16, p. 1885-1896, 2021.
KHOURY, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, v. 27, n. 7, p. 1205-1211, 2021.
LIU, Y. et al. Safety and Immunogenicity of SARS-CoV-2 BNT162b2 mRNA Vaccine in Adolescents. New England Journal of Medicine, v. 384, n. 18, p. 1719-1731, 2021.
LURIE, N. et al. Developing Covid-19 Vaccines at Pandemic Speed. New England Journal of Medicine, v. 382, n. 21, p. 1969-1973, 2020.
MASSARANI, Luisa Medeiros; BROTAS, Antonio; COSTA, Márcia Cristina Rocha; NEVES, Luiz Felipe Fernandes. Vacinas contra a COVID-19 e o combate à desinformação na cobertura da Folha de S. Paulo. Fronteiras – Estudos Midiáticos, São Leopoldo, v. 23, n. 2, p. 29-43, maio/ago. 2021.
MODERNA, N.; YOUNG, L.; IVERSEN, P. et al. Safety and efficacy of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, v. 386, n. 5, p. 447-458, 2022.
MULLOOLY, J. P. et al. Risk of Hospitalization for Coronavirus Disease 2019 (COVID-19) Among Older Adults With SARS-CoV-2 Infection in the Community: A Cohort Study. Clinical Infectious Diseases, v. 73, n. 3, p. e690-e697, 2021.
OMER, S. B. et al. Vaccine allocation under uncertainty: Insights from COVID-19. Science, v. 370, n. 6519, p. 1270-1273, 2020.
PATEL, M. M. et al. Persistence of Antibodies and Cellular Immune Responses Post mRNA COVID-19 Vaccination in Healthcare Workers. MedRxiv, 2022. DOI: 10.1101/2022.01.05.22268049.
POLACK, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, v. 383, n. 27, p. 2603-2615, 2020.
RANZANI, Otavio T. et al. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study. Clinical Microbiology and Infection, v. 28, n. 5, p. 736. e1-736. e4, 2022.
RINALDI, M. et al. Immunogenicity of SARS-CoV-2 Messenger RNA Vaccines in Solid Organ Transplant Recipients. Transplantation, v. 106, n. 5, p. 1084-1089, 2022.
ROOD, J. E. et al. Investigational COVID-19 Vaccine Clinical Trials: An Updated Review of Safety and Efficacy Profiles. Vaccines.
SILVA, Líllian Oliveira Pereira da; NOGUEIRA, Joseli Maria da Rocha. A corrida pela vacina em tempos de pandemia: a necessidade da imunização contra a COVID-19. Revista RBAC, v. 52, n. 2, p. 149-153, 2020.
SHIMABUKURO, T. T. et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine, v. 384, n. 24, p. 2273-2282, 2021.
SMITH, N. et al. Effectiveness of COVID-19 Vaccination in Reducing SARS-CoV-2 Hospitalizations and ICU Admissions in the United States. Clinical Infectious Diseases, 2022. ciaa1846.
VILELA FILHO, Alexander de Sá et al. Vacinas para Covid-19: Uma revisão de literatura. Brazilian Journal of Development, Curitiba, v. 8, n. 1, p. 1880-1901, jan. 2022. DOI: 10.34117/bjdv8n1-121.
ZHANG, H.; ROSTAING, L.; ROURA-MIR, C. et al. Effect of SARS-CoV-2 Omicron variant on COVID-19 vaccine efficacy. The Lancet, v. 402, n. 10202, p. 380-382, 2023.
ZHAO, Y. et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduction and Targeted Therapy, v. 6, n. 1, p. 1-8, 2021.